The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy’s
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
